Primary cutaneous aspergillosis is a rare, life-threatening, infectious complication in premature infants that may result in fulminant sepsis and subsequent multi-organ failure. In the past decade, the incidence of primary aspergillosis has increased significantly, whereas the high morbidity and mortality of invasive aspergillosis remains unaltered. In vitro studies reveal that more and more Aspergillus species seem to be refractory to the classical treatment with fluconazole or amphotericin B. This case report presents two extremely low birth weight infants (ELBW) with primary cutaneous aspergillosis, which was refractory to amphotericin B. Both patients were successfully treated with systemic voriconazole, an extendedspectrum triazole antifungal, supported by topical care. This paper provides the clinical manifestation, diagnostics and pharmacotherapy of primary cutaneous aspergillosis, as well as pharmacokinetic aspects of voriconazole in ELBW infants.
Introduction
Primary cutaneous aspergillosis is a rare fungal infection in premature infants that may cause extensive tissue destruction and subsequent systemic illness leading to multi-organ failure and death. [1] [2] [3] [4] Several authors have pointed out the difficulties of an early clinical or microbiological diagnosis and have emphasized the need for an immediate and effective antifungal therapy. [1] [2] [3] Woodruff et al. 1 reviewed 16 cases of primary cutaneous aspergillosis in neonates, eight of whom died from fulminant fungal sepsis. Classical antifungal treatment did not prevent dissemination of these mold infections, which were initially limited to skin lesions. 1, 3 Although liposomal amphotericin B has been the drug of choice in these patients, [1] [2] [3] [4] several reports indicate that a substantial fraction of Aspergillus species may be refractory to amphotericin B. 1, 5, 6 During the past few years, voriconazole, an extendedspectrum triazole antifungal, has become increasingly established as an agent of choice in severe fungal infections. [5] [6] [7] [8] In vitro studies have revealed a strong fungicidal activity against Aspergillus molds.
5 A large comparative trial in immunocompromised adult patients with invasive aspergillosis established the superiority of voriconazole over amphotericin B in terms of clinical response and survival (hazard ratio for mortality 0.59). 7 Walsh et al. 8, 9 first reported on the use of voriconazole in immunocompromised pediatric patients and achieved a respectable success rate with a very low incidence of side effects.
Case reports Case 1 Case 1 was a female premature infant born in the 24th week of gestation (24 þ 1/7 weeks gestation) after amniotic infection syndrome. The birth weight was 600 g and the Apgar scores were 8, 9 and 9 at 1, 5 and 10 min, respectively. Systemic antibiotic therapy was initiated with gentamicin and mezlocillin. Antifungal prophylaxis was begun with fluconazole (3.0 mg/kg given every third day; Diflucan s , Pfizer Ltd, Karlsruhe, Germany) after placement of a silastic catheter on the third day of life (DOL 3). Initial skin swabs and blood cultures were sterile.
At DOL 5, inspection of the skin revealed a periumbilical colonization with smoky-gray removable patches of furry mold and an erythematous circular maceration with multiple tiny pustules in the subumbilical area. Because microbiological samples grew Aspergillus fumigatus, antifungal therapy with liposomal amphotericin B (AmBisome s , GILEAD Sciences GmbH, Martinsried/Planegg, Germany) was initiated (1.0 mg/kg/day increased to 3.5 mg/kg/day at day 6 in increments of 0.5 mg/kg). Local therapy included octenidine rinses (Octenisept s , Schü lke & Mayr GmbH, Norderstedt, Germany) and hydrofiber wound dressings (Aquacel s , Convatec, Princeton, NY). All cutaneous lesions resolved without significant scarring. However, at DOL 15 (day 10 of liposomal amphotericin B), a new raised erythematous plaque, 2 Â 3 cm in size, developed in the left scapular region. Multiple skin swabs and a fine-needle aspirate of the lesion revealed A. fumigatus. As this mold infection proved unresponsive to amphotericin B, after signed written consent, the systemic antifungal therapy was changed to intravenous (i.v) voriconazole (VFEND s , Pfizer Ltd, Karlsruhe, Germany) on DOL 29 (Table 1) . Topical therapy included gentian violet and cyclopiroxolamine (Batrafen s , Aventis Pharma Germany, Bad Soden am Ts., Germany). After 7 treatment days (DOL 36), the plaque was considerably reduced in size and all cultures were negative for Aspergillus. One week later (DOL 43), the i.v regimen was switched to oral administration. According to voriconazole plasma levels, the dose was increased after 12 oral treatment days (DOL 55), on account of persisting pustules deep in the tissue. All systemic and local antifungals were discontinued on treatment day 55 (DOL 83) of voriconazole treatment, leaving only a minor scar in the left scapular region.
Case 2
Case 2 was a male premature infant born in the 23th week of gestation (23 þ 1/7 weeks gestation) via cesarean section after amniotic infection syndrome. The birth weight was 540 g and the Apgar scores were 9, 9 and 9 at 1, 5 and 10 min, respectively. Systemic antibiotic therapy included gentamicin and mezlocillin. Antibiotic prophylaxis with vancomycin (10.0 mg/kg/day) and antifungal prophylaxis with fluconazole (3.0 mg/kg given every third day) were initiated. Initial skin swabs and blood cultures were sterile. A silastic central venous catheter was placed at DOL 5.
At DOL 7, the umbilicus was found to be covered with smokygray removable patches, and multiple macerating skin lesions had developed, predominantly on the lower abdomen and the left leg. The antifungal regimen was switched to liposomal amphotericin B (1.0 mg/kg/day increased to 2.5 mg/kg/day at day 4 in increments of 0.5 mg/kg). During amphotericin B therapy, the macerating erythematous skin lesions disseminated throughout the ventral chest, the whole abdomen and the left leg (see Figure 1) . As samples from the affected area were repeatedly positive for Aspergillus niger, after signed written consent, on DOL 12 the systemic antifungal therapy was changed to intravenous voriconazole (Table 2) . Topical care was also initiated, consisting of gentian violet and cyclopiroxolamine. After 12 days (DOL 24), the abdominal skin was nearly restored, and all cultures were negative for Aspergillus. After 18 days (DOL 30), the i.v. therapy was switched to oral administration ( Table 2 ). All systemic and local antifungals were discontinued on day 28 of voriconazole treatment (DOL 40). Only a superficial scar on the lower abdomen remained.
Clinical pharmacology
Voriconazole peak and trough plasma levels were determined repeatedly, using a validated HPLC chromatographic assay 10 at a detection threshold of 0.2 mg/ml. Interpretation was based on ranges reported in the literature. 5, 11 Owing to the lack of data on the pharmacokinetics in premature infants and the interindividual 
Figure 1
Amphotericin B and voriconazole against Aspergillus k Frankenbusch et al variability of voriconazole plasma levels, 5, 6 our dose adjustments were based on the clinical response. In case 1, the administration was switched from i.v. to oral on DOL 43, because the laboratory cultures were negative and the clinical condition had improved. The oral administration was to ensure complete resolution. However, the oral dosage was then increased on DOL 55, because there were persisting deep pustules in the left scapular region yet the plasma levels seemed subtherapeutic (Table 1) .
In case 2, the skin lesions healed rapidly during the 2 weeks of i.v. treatment, so administration was switched to oral after 18 days (DOL 30). The oral dosage was then never increased because the skin continued improving, despite low plasma levels ( Table 2) . There was no evidence of side effects or changes in serum electrolyte concentrations for either patient.
Discussion
Both of our patients presented primary cutaneous aspergillosis, confirmed by laboratory cultures, which was refractory to amphotericin B. They were both successfully treated with i.v. voriconazole supported by topical treatment, without noticeable side effects. All lesions healed without surgical intervention, leaving only minor scars. Systemic dissemination -and the concomitant risk of mortality by multi-organ failure -was successfully prevented in both cases.
The available data from our two patients cannot definitively discern the mechanism of the successful treatment, but there are several reasons to believe that the voriconazole was mainly responsible. First, in both patients 2 weeks after changing the regimen from conventional antifungal treatment to intravenous voriconazole and topical treatment, the clinical symptoms were largely resolved and cultures were negative. Second, the Aspergillus had deeply infiltrated the tissue in both patients; only the systemic therapy of voriconazole would have reached the infection at that level. Third, in vitro studies show a very high fungicidal activity of voriconazole against Aspergillus mold because of its particular capability to disrupt synthesis of the fungal plasma membrane, which is an essential step for fungal proliferation. 5, 6 Fourth, clinical studies have shown voriconazole alone to be effective treatment of invasive fungal infections in immunocompromised pediatric 8, 9 and adult patients. 5, 7 Nonetheless, the topical treatment presumably contributed also to the cure. The macerations were too widespread to be effectively reduced by external treatment alone, but the anifungal effects of cyclopiroxolamine restricted the colonization of Aspergillus on the skin surface. Moreover, the combination of gentian violet and cyclopiroxolamine dried out and granulated the skin; so these areas became unfavorable for fungal growth.
In the literature, there are no validated therapeutic ranges for voriconazole in neonates and premature infants. We found that i.v. maintenance administration at a dosage of 4 mg/kg/day was clinically effective within 2 weeks. We then switched to oral administration as maintenance therapy to assure complete clearance. At this stage of oral administration, we used a dosage that resulted in low plasma levels compared to those in adults. 5, 11 In the second case, this was sufficient for successful resolution. In the first case though, at these low plasma levels, some fungal infiltrations persisted deeply embedded in the tissue. Therefore, we raised the oral dosage, and eventually the infection resolved completely. From our viewpoint, serum levels do not directly relate to improvement or toxicity, because of the high bioavailability of voriconazole. The dosage may be titrated according to the clinical response and the monitoring of the plasma level will serve primarily to avoid organ toxicity. 5, 12, 13 The cases presented here support the results of previous studies in infants and children showing successful use of voriconazole to treat severe fungal skin infections. 8, 9, 12 Voriconazole apparently prevented life-threatening systemic dissemination of the mold infection, resulting in a vastly improved outcome compared to previous reports on this condition in premature infants. 
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